Joanne Holland
Direttore Tecnico/Scientifico/R&S presso CONDUIT PHARMACEUTICALS INC.
Profilo
Joanne Holland is the founder of Nuformix Plc, which was founded in 2008.
She held the title of Executive Director in 2021.
Currently, Dr. Holland is the Chief Scientific Officer at Conduit Pharmaceuticals, Inc. since 2024.
Previously, she worked at Nuformix Technologies Ltd.
as the Director, Chief Scientific & Technology Officer from 2008 to 2021.
Dr. Holland obtained a doctorate degree from the University of Leeds.
Posizioni attive di Joanne Holland
| Società | Posizione | Inizio |
|---|---|---|
| CONDUIT PHARMACEUTICALS INC. | Direttore Tecnico/Scientifico/R&S | 19/03/2024 |
Precedenti posizioni note di Joanne Holland
| Società | Posizione | Fine |
|---|---|---|
Nuformix Technologies Ltd.
 Nuformix Technologies Ltd. Pharmaceuticals: MajorHealth Technology Nuformix Technologies Ltd. engages in investment in pharmaceutical products. Its activities include development and discovery of patented novel cocrystal forms of approved small molecules, creating an IP portfolio containing 14 granted patents covering cocrystal forms of five small molecule drugs. It offers the NXP001 and NXP002. The company was founded by Dr. David Joszef Tapolzcay and Dr. Daniel Gooding on October 23, 2007 and is headquartered in Cambridge, the United Kingdom. | Direttore Tecnico/Scientifico/R&S | 31/05/2021 |
| NUFORMIX PLC | Fondatore | 31/05/2021 |
Formazione di Joanne Holland
| University of Leeds | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| NUFORMIX PLC | Health Technology |
| CONDUIT PHARMACEUTICALS INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Nuformix Technologies Ltd.
Nuformix Technologies Ltd. Pharmaceuticals: MajorHealth Technology Nuformix Technologies Ltd. engages in investment in pharmaceutical products. Its activities include development and discovery of patented novel cocrystal forms of approved small molecules, creating an IP portfolio containing 14 granted patents covering cocrystal forms of five small molecule drugs. It offers the NXP001 and NXP002. The company was founded by Dr. David Joszef Tapolzcay and Dr. Daniel Gooding on October 23, 2007 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Joanne Holland
